Hwail Pharmaceutical Co.Ltd (061250) — Cash Flow-to-Debt Ratio
Hwail Pharmaceutical Co.Ltd (061250) has a Cash Flow-to-Debt Ratio of 1.29x as of September 2025, meaning its operating cash flow of ₩6.82 Billion could theoretically repay 1% of its total liabilities (₩5.29 Billion) in one year. See Hwail Pharmaceutical Co.Ltd financial flexibility index to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Hwail Pharmaceutical Co.Ltd Cash Flow-to-Debt Ratio (2011–2024)
Historical debt coverage capacity for Hwail Pharmaceutical Co.Ltd across 14 annual periods. For the full cash flow conversion analysis, see cash flow conversion of Hwail Pharmaceutical Co.Ltd.
Annual Cash Flow-to-Debt Ratio for Hwail Pharmaceutical Co.Ltd (2011–2024)
Year-by-year debt coverage analysis for Hwail Pharmaceutical Co.Ltd. Check Hwail Pharmaceutical Co.Ltd (061250) cash earnings ratio to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (KRW) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | 0.95x | ₩11.63 Billion | ₩12.19 Billion | ▲ +56.8% |
| 2023 | 0.61x | ₩7.02 Billion | ₩11.55 Billion | ▲ +2710.7% |
| 2022 | -0.02x | ₩-233.56 Million | ₩10.02 Billion | ▼ -101.4% |
| 2021 | 1.61x | ₩20.09 Billion | ₩12.49 Billion | ▲ +10321.0% |
| 2020 | -0.02x | ₩-201.69 Million | ₩12.82 Billion | ▼ -108.5% |
| 2019 | 0.18x | ₩3.69 Billion | ₩19.97 Billion | ▼ -42.8% |
| 2018 | 0.32x | ₩7.17 Billion | ₩22.16 Billion | ▼ -0.2% |
| 2017 | 0.32x | ₩8.34 Billion | ₩25.72 Billion | ▼ -2.7% |
| 2016 | 0.33x | ₩9.58 Billion | ₩28.76 Billion | ▲ +299.4% |
| 2015 | -0.17x | ₩-6.90 Billion | ₩41.33 Billion | ▼ -103.2% |
| 2014 | -0.08x | ₩-2.78 Billion | ₩33.85 Billion | ▼ -143.3% |
| 2013 | 0.19x | ₩6.97 Billion | ₩36.71 Billion | ▲ +484.3% |
| 2012 | 0.03x | ₩1.00 Billion | ₩30.92 Billion | ▼ -87.9% |
| 2011 | 0.27x | ₩7.86 Billion | ₩29.24 Billion | — |